S

Sanofi

Global pharma company; vaccines and R&D

Planning Analytics Business Enablement Analyst

Full-TimeUpdated on 10/16/2026Deadline 11/30/26
HUF10.9M - HUF14.6M
Mid, Senior
Budapest, Hungary
HybridHybrid schedule: 60% on-site and 40% remote.
Business & StrategyBusiness Analysis

About the job

Requirements
  • Three to five years of experience in Finance, Controlling, FP&A, Data/Analytics, or system support roles.
  • A solid understanding of testing and project methodologies, including Agile and Waterfall.
  • Ability to coordinate activities and manage workstreams, and analyze data or test outcomes.
  • Clear and concise verbal and written communication with team members and stakeholders, adapting communication style as needed.
  • Ability to manage assigned tasks and deadlines, prioritize work, and balance multiple responsibilities.
  • Ability to take initiative to identify and flag potential issues early.
Responsibilities
  • Support functional design and deployment activities for global Planning Analytics (TM1) solutions used for budgeting, forecasting, and operational planning.
  • Coordinate project documentation, perform analysis, prepare testing materials, and support user communities in collaboration with the Enablement Lead and project teams.
  • Contribute to Planning Analytics project lifecycle activities, including requirements clarification, documentation, testing, knowledge transfer, and deployment.
  • Ensure complete, accurate, and up-to-date project documentation throughout all project phases.
  • Lead the User Acceptance Testing process, including preparing and executing test scripts and reporting defects.
  • Contribute to capturing business requirements and preparing functional documentation.
  • Coordinate change management, training material preparation, and knowledge transfer.
  • Manage demand intake and governance by capturing stakeholder requirements, maintaining demand records in SharePoint and Jira, and ensuring alignment with project priorities and resource constraints.
  • Make independent decisions within established guidelines on test prioritization, documentation standards, and support resolution, in alignment with the Enablement Lead's oversight.
  • Create, maintain, and update project documentation, including functional specifications, operational guides, test scripts, and data dictionaries.
  • Ensure document version control, consistency, and proper archival management while coordinating inputs from multiple stakeholders.
  • Track project progress, issues, and changes, and provide status reporting to leadership.
  • Coordinate demand governance activities and provide analysis to support prioritization and resource planning decisions.
  • Manage and document requirements-gathering sessions by analyzing, collecting, and synthesizing stakeholder inputs and process flows.
  • Conduct gap analysis initiatives by compiling findings and providing actionable insights to support solution design.
  • Develop and coordinate test cases and scenarios covering functional requirements, integration points, and business processes, with risk-based prioritization.
  • Execute test protocols, document results, identify defects, and coordinate resolution activities with technical teams.
  • Guide User Acceptance Testing participants through testing processes, clarifying procedures and expected outcomes.
  • Create training materials and user guides to support system rollouts and process changes.
  • Own and execute change management communication strategies and lead user feedback sessions to drive continuous improvement.
  • Deliver first-line functional support during hypercare periods, document user issues, and provide timely resolutions.
  • Manage and implement knowledge transfer to operational teams to support sustainable long-term operations.
Desired Qualifications
  • Exposure to system implementation and/or enhancement projects.
  • Experience preparing structured documentation, training materials, and system and/or operational specifications.
  • Some experience with testing or User Acceptance Testing activities.
  • Basic understanding of planning tools such as TM1, Anaplan, or BPC.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...